|96.070||+0.1700||+0.18%||Vol 200||1Y Perf -3.69%|
|Dec 2nd, 2021 20:10|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★ 56.54|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★ 59.75|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★★+ 48.52|
|Price Range Ratio 52W %||30.63||Earnings Rating||—|
|Market Cap||-||Earnings Date||-|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||5.34K|
|Avg. Monthly Volume||29.58K|
|Avg. Quarterly Volume||20.98K|
Mon, 29 Nov 2021 12:25 GMT Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Novavax (NVAX)- TipRanks. All rights reserved.
Thu, 28 Oct 2021 12:47 GMT Sanofi (SNYNF) Received its Third Buy in a Row- TipRanks. All rights reserved.
Tue, 10 Aug 2021 09:54 GMT Sanofi (SNYNF) Receives a Buy from J.P. Morgan- TipRanks. All rights reserved.
Tue, 10 Aug 2021 09:54 GMT Sanofi (SNYNF) Gets a Buy Rating from Goldman Sachs- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.